Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel

Novartis

WEBSITE BSE:500672 NSE: NOVARTIS Inc. Year: 1947 Industry: Trading My Bucket: Add Stock

₹962 -23.9 | 2.4%

Last updated: 15:59

Consolidated Standalone

Last updated: 15:59

Novartis Overview

Novartis India Ltd manufactures tablets, drugs and allied merchandise. The Company is engaged in the wholesale of pharmaceuticals and clinical goods. The Company makes a speciality of over three divisions, along with prescription drugs, eye care and ordinary drug treatments. The Pharmaceuticals segment consists of a portfolio of prescription drug treatments, that are given to patients via healthcare specialists. Its Pharmaceutical business is focused on bone and pain, calcium portfolio, gynaecology and neurosciences. The prescribed drugs divisi...Read More

Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

Novartis Key Financials

Market Cap ₹2375 Cr.

Stock P/E 23.5

P/B 3

Current Price ₹962

Book Value ₹ 320.4

Face Value 5

52W High ₹1099.9

Dividend Yield 2.6%

52W Low ₹ 747.6

Edit Ratio

Novartis Share Price

₹ | |

Volume
Price

Novartis Quarterly Price

Quarterly Monthly
Show Value Show %

Novartis Peer Comparison

Novartis Quarterly Results

#(Fig in Cr.) Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Net Sales 79 85 81 92 87 93 84 88 90 86
Other Income 17 22 10 10 10 11 11 11 9 9
Total Income 96 107 92 103 97 104 95 98 100 95
Total Expenditure 62 65 70 68 69 67 60 60 66 64
Operating Profit 34 42 22 34 28 36 35 38 33 31
Interest 1 0 0 0 0 0 0 0 0 1
Depreciation 1 0 0 1 1 1 1 1 1 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 32 41 21 34 28 35 34 37 33 30
Provision for Tax 9 15 7 8 7 10 5 10 8 14
Profit After Tax 24 27 15 26 20 25 29 28 24 16
Adjustments 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 24 27 15 26 20 25 29 28 24 16
Adjusted Earnings Per Share 9.6 10.8 5.9 10.4 8.3 10.3 11.9 11.2 9.8 6.5

Novartis Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 873 690 656 564 491 438 381 400 379 335 356 348
Other Income 112 245 72 174 78 36 34 34 58 62 42 40
Total Income 985 934 728 738 569 475 416 433 437 397 398 388
Total Expenditure 881 659 632 572 479 427 356 373 314 270 265 250
Operating Profit 104 275 96 166 91 48 60 60 123 127 133 137
Interest 0 0 1 6 2 6 8 5 2 1 1 1
Depreciation 4 3 4 3 3 13 12 10 6 3 2 3
Exceptional Income / Expenses -6 0 0 0 0 0 0 -50 0 0 0 0
Profit Before Tax 93 272 92 158 86 29 40 -4 115 123 130 134
Provision for Tax 14 73 35 79 34 19 19 -0 12 38 30 37
Profit After Tax 79 198 57 78 52 10 21 -4 103 85 101 97
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 79 198 57 78 52 10 21 -4 103 85 101 97
Adjusted Earnings Per Share 24.8 62 20.3 31.8 21 4.1 8.5 -1.5 41.9 34.5 40.9 39.4

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 6% -4% -4% -9%
Operating Profit CAGR 5% 30% 23% 2%
PAT CAGR 19% 0% 59% 2%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 17% 18% 8% 2%
ROE Average 13% 13% 8% 8%
ROCE Average 17% 16% 11% 12%

Novartis Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 1002 1194 920 734 759 721 711 692 776 745 785
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 0 0 0 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 697 142 828 898 891 987 1131 984 1008 716 697
Total Current Liabilities 362 204 320 481 367 417 357 334 268 400 426
Total Liabilities 2060 1540 2070 2113 2018 2125 2199 2010 2052 1861 1908
Fixed Assets 9 6 6 5 15 76 64 24 19 7 5
Other Non-Current Assets 837 270 953 1004 1014 1052 1213 1160 1246 912 873
Total Current Assets 1215 1264 1110 1103 988 996 921 826 786 942 1030
Total Assets 2060 1540 2070 2113 2018 2125 2199 2010 2052 1861 1908

Novartis Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 15 637 25 76 38 88 79 68 158 19 45
Cash Flow from Operating Activities -60 57 -41 161 -194 -23 -69 39 45 113 75
Cash Flow from Investing Activities 719 -630 424 69 274 56 95 87 -153 33 -3
Cash Flow from Financing Activities -38 -39 -332 -268 -30 -41 -37 -36 -30 -121 -64
Net Cash Inflow / Outflow 622 -612 51 -38 50 -9 -11 90 -139 26 7
Closing Cash & Cash Equivalent 637 25 76 38 88 79 68 158 19 45 52

Novartis Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 24.75 62.04 20.33 31.75 20.98 4.08 8.47 -1.51 41.88 34.52 40.88
CEPS(Rs) 26.01 63.14 21.61 32.78 22.27 9.41 13.4 2.4 44.34 35.58 41.77
DPS(Rs) 10 10 10 10 10 10 10 10 47.5 25 25
Book NAV/Share(Rs) 313.51 375.63 329.45 299.77 309.34 293.36 289.36 281.17 314.3 301.79 318.06
Core EBITDA Margin(%) -0.89 4.47 3.74 -1.2 2.06 2.2 5.66 5.5 15.74 17.79 23.44
EBIT Margin(%) 10.69 39.41 14.09 23.82 14.82 6.58 10.52 0.21 28.33 33.89 33.63
Pre Tax Margin(%) 10.66 39.38 13.98 23.01 14.55 5.38 8.82 -0.78 27.9 33.49 33.43
PAT Margin (%) 9.05 28.74 8.72 11.45 8.78 1.89 4.61 -0.76 25 23.22 25.87
Cash Profit Margin (%) 9.51 29.25 9.27 11.82 9.32 4.36 7.29 1.22 26.46 23.93 26.43
ROA(%) 3.89 11.01 3.17 3.75 2.51 0.49 0.97 -0.18 5.09 4.35 5.35
ROE(%) 8.06 18.01 5.38 9.4 6.89 1.36 2.91 -0.53 14.07 11.21 13.19
ROCE(%) 9.52 24.77 8.75 19.72 11.7 4.73 6.67 0.14 15.96 16.35 17.15
Receivable days 33.46 35.2 25.31 22.59 27.72 28.5 30.7 31.23 35.62 38.62 38.18
Inventory Days 42.48 45.59 44.47 38.41 36.25 40.83 42.89 39.38 49.34 49.54 40.22
Payable days 105.65 104.65 85.19 133.31 181.45 164.16 159.09 130.52 119.32 110.74 101.73
PER(x) 22.72 10.45 33.26 19.28 32.69 122.97 65.18 0 13.5 29.8 19.2
Price/Book(x) 1.79 1.73 2.05 2.04 2.22 1.71 1.91 2.1 1.8 3.41 2.47
Dividend Yield(%) 1.78 1.54 1.48 1.63 1.46 1.99 1.81 1.69 8.4 2.43 3.18
EV/Net Sales(x) 1.1 1.37 1.66 1.31 2.2 1.5 2.26 2.35 2.22 5.8 3.62
EV/Core EBITDA(x) 9.24 3.44 11.32 4.45 11.93 13.65 14.42 15.58 6.81 15.3 9.67
Net Sales Growth(%) 1.29 -21.02 -4.86 -14.07 -12.98 -10.69 -12.98 4.86 -5.28 -11.53 6.33
EBIT Growth(%) 3.63 190.97 -66 76.37 -46.42 -59.9 36.23 -97.88 0 6.15 5.52
PAT Growth(%) -19.71 150.65 -71.14 36.95 -33.93 -80.53 107.34 -117.8 2878.49 -17.58 18.44
EPS Growth(%) -19.71 150.65 -67.23 56.14 -33.93 -80.53 107.34 -117.8 2878.48 -17.58 18.44
Debt/Equity(x) 0 0 0 0 0 0 0 0 0 0 0
Current Ratio(x) 3.36 6.18 3.47 2.3 2.69 2.39 2.58 2.47 2.93 2.36 2.42
Quick Ratio(x) 3.08 5.99 3.19 2.18 2.52 2.25 2.45 2.3 2.73 2.24 2.32
Interest Cover(x) 444.95 1294.67 128.4 29.48 54.94 5.48 6.21 0.21 66.93 83.44 170.38
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0 0 0

Novartis Shareholding Pattern

# Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Promoter 70.68 70.68 70.68 70.68 70.68 70.68 70.68 70.68 70.68 70.68
FII 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.17
DII 0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.62 0.52
Public 28.61 28.61 28.61 28.61 28.61 28.61 28.61 28.61 28.51 28.63
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Novartis News

Novartis Pros & Cons

Pros

  • Company has delivered good profit growth of 58% CAGR over last 5 years
  • Debtor days have improved from 110.74 to 101.73days.
  • Company is almost debt free.

Cons

  • Company has a low return on equity of 13% over the last 3 years.

* The pros and cons are machine generated.

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares
whatsapp

Please Login!

Click to Login
OR
Get free Account

Error!